4,886 research outputs found
Differenze di genere nei neonati figli di madri diabetiche
No full textAims:
to evaluate two populations of women: one consisting of patients with type I diabetes mellitus (DMI) and another from patient with gestational diabetes mellitus (GMD) and the prevalence of maternal-fetal and neonatal outcomes based on gender differences.Methods: Retrospective study of 57 pregnant women with DMI (24 women, 43%) and GDM (33 women, 57%). Inclusion criteria were: single pregnancy, pregestational diagnosis of type I diabetes. We reported the type of insulin and the number of units per day which was self-administered. We reported the duration of pregnancy, any comorbidities and the value of glycated hemoglobin, whenever possible, in the first trimester of pregnancy. Each woman's obstetric history has been collected as nulliparity, multiparity, history of previous abortions, a history of previous fetal deaths and pre-eclampsia. Obstetric maternal-fetal outcomes we analyzed were: pre-eclampsia, elective caesarean section performed or urgency, preterm birth, P-PROM, polyhydramnios, placental abruption, stillbirth and perinatal death and other obstetric complications related to underlying disease. We also considered the percentage of infants admitted to NICU for the appearance of acute respiratory distress syndrome and low Apgar score at 5 minutes after birth.Results: Although not statistically significant our study has shown that some maternal fetal outcomes such as RDS and IUGR affect predominantly fetal-neonatal male population, especially in the Group of patients with DMI.Conclusions: We reported gender difference in materno-fetal outcomes in diabetic pregnant women but further studies on larger sample size are needed before drawing definitive conclusions
Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis
No full textIntroduction and hypothesis The aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI).
Methods A systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018.
Results Eight full texts were evaluated but only five were selected for the qualitative and quantitative analyses. Duration of
follow-up after Urolastic® injections was significantly heterogeneous, ranging from 6 to 24 months. Secondary injections were needed in 16.7%–35.0% of the treated patients. The pooled proportion of secondary injections was 20% (95% CI: 15%–24%; I2:0%). Subjective improvement, measured by different means (i.e., patient global impression of improvement PGI-I score) was only assessed by 40% of the selected papers and was > 80% in two cohorts. The objective treatment success was evaluated by four (80.0%) papers and was achieved in all cohorts with a wide proportional range: from 32.7% (i.e., patients without objective SUI symptomcough tests and with a negative pad test) to 67.0%. Its pooled proportionwas 57%(95% CI: 38%–75%; I2: 82.3%).
Conclusions Urolastic® showed effectiveness in patients with SUI during a follow-up period of 6–24 months
Francesco Scorza Barcellona o della passione agiografica
No full textL'autrice traccia, sul filo dei ricordi, il profilo scientifico ed umano di Francesco Scorza Barcellona ed introduce gli studi raccolti nel volume.The author traces, on the thread of memories, the scientific and human profile of Francesco Scorza Barcelona and introduces the studies collected in the book
Delle lodi di don Francesco Medici de' principi di Toscana : orazione /
No full textEngraved t.p. vignette of Medici arms. On recto of 2nd leaf is Callot's full-page engraved port. of Francesco de' Medici, son of Grand Duke Ferdinand I. It is in Lieure's 1st state. The port. also appeared the same year in Alessandro Adimari's Esequie dell' ill.mo & ecc.mo principe don Francesco Medici (Florence : Gio. Donato & Bernardino Giunti); see Lieure. Large woodcut Giunti device on p. [31].Lieure, J. Jacques Callot,Mode of access: Internet.At head of front pastedown is bookplate of Francesco Riccardi de Vernaccia (Florence, ca. 1780; see Gelli, p. 387). Below it is the label of Horatius (Orazio) Landau, with stamped shelfmark 53021. At foot is the bookplate of U. Manganelli, signed with the initials SER. A dedicatory inscription at foot of t.p. has been scratched out.Binding: modern marbled paper, backed in green vellum. Date, author & title writte on spine.Port. trimmed into the image at right margin and foot
Frankenstein
No full text@inproceedings{orsini2015graph,
title={Graph invariant kernels},
author={Orsini, Francesco and Frasconi, Paolo and De Raedt, Luc},
booktitle={IJCAI Proceedings-International Joint Conference on Artificial Intelligence. IJCAI},
year={2015}
Use of Azithromycin in Pregnancy: More Doubts than Certainties
No full textMacrolides such as azithromycin are commonly prescribed antibiotics during pregnancy. The good oral bioavailability and transplacental transfer of azithromycin make this drug suitable for the treatment of sexually transmitted diseases, toxoplasmosis, and malaria. Moreover, azithromycin is useful both in the management of preterm pre-labor rupture of membranes and in the adjunctive prophylaxis for cesarean delivery. The aim of this comprehensive narrative review is to critically analyze and summarize the available literature on the main aspects of azithromycin use in pregnant women, with a special focus on adverse offspring outcomes associated with prenatal exposure to the drug. References for this review were identified through searches of MEDLINE, PubMed, and EMBASE. Fetal and neonatal outcomes following prenatal azithromycin exposure have been investigated in several studies, yielding conflicting results. Increased risks of spontaneous miscarriage, major congenital malformations, cardiovascular malformations, digestive system malformations, preterm birth, and low birth weight have been reported in some studies but not in others. Currently, there is no conclusive evidence to support that azithromycin use by pregnant women causes adverse outcomes in their offspring. Therefore, this agent should only be used during pregnancy when clinically indicated, if the benefits of treatment are expected to outweigh the potential risks
- …
